A randomized, double-blind, crossover, placebo-controlled trial of 6 weeks benfotiamine treatment on postprandial vascular function and variables of autonomic nerve function in Type 2 diabetes

Diabetic Medicine

Volumn 30, Issue 10, 2013, Pages 1204-1208

  Stirban, A ^a,b   Pop, A ^a   Tschoepe, D ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b Profil Institute for Metabolic Research GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BENFOTIAMINE; PLACEBO;

ADULT; AGED; ARTICLE; AUTONOMIC NERVE; BLOOD VESSEL INJURY; BLOOD VESSEL PARAMETERS; CLINICAL ARTICLE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DETERIORATION; DIABETIC PATIENT; DIET RESTRICTION; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FLOW MEDIATED DILATATION; FUNCTION TEST; HEART RATE VARIABILITY; HUMAN; HYPEREMIA; LASER DOPPLER FLOWMETRY; LONG TERM CARE; NERVE FUNCTION; NON INSULIN DEPENDENT DIABETES MELLITUS; POPULATION; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION;

ADULT; AGED; ANTIOXIDANTS; AUTONOMIC PATHWAYS; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIABETIC NEUROPATHIES; DOUBLE-BLIND METHOD; ENDOTHELIUM, VASCULAR; FASTING; FEMALE; HUMANS; LASER-DOPPLER FLOWMETRY; MALE; MICROCIRCULATION; MIDDLE AGED; PILOT PROJECTS; POSTPRANDIAL PERIOD; THIAMINE;

EID: 84884724567     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/dme.12240     Document Type: Article

References (17)

1. Hadi HA, Carr CS, Al SJ. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005; 1: 183-198.
2. Neunteufl T, Heher S, Katzenschlager R, Wolfl G, Kostner K, Maurer G et al. Late prognostic value of flow-mediated dilation in the brachial artery of patients with chest pain. Am J Cardiol 2000; 86: 207-210.
3. Neunteufl T, Katzenschlager R, Hassan A, Klaar U, Schwarzacher S, Glogar D et al. Systemic endothelial dysfunction is related to the extent and severity of coronary artery disease. Atherosclerosis 1997; 129: 111-118.
4. Takase B, Matsushima Y, Uehata A, Ishihara M, Kurita A. Endothelial dysfunction, carotid artery plaque burden, and conventional exercise-induced myocardial ischemia as predictors of coronary artery disease prognosis. Cardiovasc Ultrasound 2008; 6: 61.
5. Guerci B, Kearney-Schwartz A, Bohme P, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 1: physiology and methods for exploring the endothelial function. Diabetes Metab 2001; 27: 425-434.
6. Guerci B, Bohme P, Kearney-Schwartz A, Zannad F, Drouin P. Endothelial dysfunction and type 2 diabetes. Part 2: altered endothelial function and the effects of treatments in type 2 diabetes mellitus. Diabetes Metab 2001; 27: 436-447.
7. Negrean M, Stirban A, Stratmann B, Gawlowski T, Horstmann T, Gotting C et al. Effects of low- and high-advanced glycation end product meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 2007; 85: 1236-1243.
8. Ceriello A, Cavarape A, Martinelli L, Da RR, Marra G, Quagliaro L et al. The postprandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med 2004; 21: 171-175.
9. Tushuizen ME, Diamant M, Heine RJ. Postprandial dysmetabolism and cardiovascular disease in type 2 diabetes. Postgrad Med J 2005; 81: 1-6.
10. O'Keefe JH, Bell DS. Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 2007; 100: 899-904.
11. Hammes HP, Du X, Edelstein D, Taguchi T, Matsumura T, Ju Q et al. Benfotiamine blocks three major pathways of hyperglycemic damage and prevents experimental diabetic retinopathy. Nat Med 2003; 9: 294-299.
12. Berrone E, Beltramo E, Solimine C, Ape AU, Porta M. Regulation of intracellular glucose and polyol pathway by thiamine and benfotiamine in vascular cells cultured in high glucose. J Biol Chem 2006; 281: 9307-9313.
13. Schmid U, Stopper H, Heidland A, Schupp N. Benfotiamine exhibits direct antioxidative capacity and prevents induction of DNA damage in vitro. Diabetes Metab Res Rev 2008; 24: 371-377.
14. Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in Diabetic Polyneuropathy (BENDIP): results of a randomised, double-blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 2008; 116: 600-605.
15. Stirban A, Negrean M, Stratmann B, Gawlowski T, Horstmann T, Gotting C et al. Benfotiamine prevents macro- and microvascular endothelial dysfunction and oxidative stress following a meal rich in advanced glycation end products in individuals with type 2 diabetes. Diabetes Care 2006; 29: 2064-2071.
16. Stirban A, Laude D, Elghozi JL, Sander D, Agelink MW, Hilz MJ et al. Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. Diabetes Metab Res Rev 2009; 25: 136-143.
17. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J et al. Endothelial function and dysfunction. Part II: association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005; 23: 233-246.